A CRO pioneer, born phygital.
Phygital means the study travels to the participant — at home, in the community, at a pharmacy or at a hospital — in one governed ecosystem. Evidilya turns clinical and real-world data into regulatory-grade evidence, across the whole arc from protocol to publication.
Born in Europe. Built for global evidence.
Europe teaches research to work across many health systems, many languages and exacting standards of care. Founded in Milan, Evidilya was built for that breadth from the start, and carries the same model wherever a study goes.
See our global reach
Scientists building for scientists.
Seventeen years of studies, never once on paper: first for investigators, then taking them to the participant. Evidilya is the operator we wanted on the other side of the protocol — for participants, for sites, for sponsors.
Better care. Better therapies. More years lived well.
We exist to make those provable – with evidence drawn from real lives, including the lives research usually leaves out, and held to a standard regulators, clinicians and payers can act on.
A world where evidence keeps pace with life.
Research that runs continuously, reaches everyone it should, and turns what happens in real life into proof health systems can act on – right when they need it.
We build the study around the participant.
Centralised, hybrid or fully decentralised – the model follows the evidence you need. We run the whole arc, from the evidence question to the published result, in one digital ecosystem, with our team from start to finish.
From prescription medicine to everyday nutrition, one scientific standard.
A cardiometabolic or rare-disease question can run as a pharmaceutical trial, a consumer-health claim study, a functional-food intervention or a connected-device performance study. The therapeutic question stays constant; the product reality changes – and the method travels across all four.
People means all of them: participants, the clinicians who see them, and the researchers who turn what happens into evidence.
When the two pull against each other, the person comes first – every design decision, from where a study happens to what we ask of a participant, is made in that order.
Evidilya
Evidilya is the union of evidence and idyll, the idyll of evidence.
It describes the state we work toward: a research environment where real-world data, rigorous science and the human experience flow together without friction. Where evidence is not an obstacle, but a clarity that lets health systems decide with confidence.
Three interlocking capabilities in one team. The combination that keeps every study faster, cleaner and more defensible than the last.
Human data science
Turning people's self-reported health into validated, analysable outcomes, subjective experience made measurable.
Real-world expertise
Clinicians, scientists and operators embedded where care actually happens, observing, listening and mapping behaviour in real settings.
Exponential technology
ECS® orchestrates the study; AIRA compounds the evidence; adaptive operations deployment puts both to work in the setting each study needs. Every trial leaves the next one cleaner, and ready to hand to a regulator.
A global study steering committee leads operations, technology, safety & vigilance, medical, scientific, biometrics, regulatory and quality. Below it works a local/global task force, extended by a qualified vendor and partner network activated study by study, all resting on our QMS and digital infrastructure.
Conviction brought us here.
Long before the industry had a name for it, our founding team was taking research to participants where they live. Not because it was strategy, but because it was the right way to listen to people.
Today that way of working has become the model regulators, sites and sponsors ask for. The conviction stays the same: more people reached, more evidence gathered, more studies meeting care where it actually happens.
Our founding team was running studies with participants in their own contexts before 'DCT' was an industry acronym.
What once required conviction is now recognised practice: the same approach, now shared by regulators and sites.
More sponsors choose this model, and more studies reach the people research should always include.
Built for real-world research from day one, with no legacy stack to retrofit.
Hubs in EMEA, APAC and North America, extended to LATAM, one operating model, local execution virtually wherever people live.
One operating model, one QMS, one point of accountability, from protocol to publication.
The full Evidilya story, in one document.
For analysts, journalists and prospective partners, a single PDF that covers our mission, capabilities, ECS® and AIRA, and the operating model behind the evidence we deliver.
Company Profile 2026
Purpose, vision and mission, and how Evidilya makes science succeed by reaching people: PHYGITAL-CROWD reach, ECS® the virtual research ecosystem, Direct-to-Participant as the default execution model, People & Research First®, AIRA, four domains, ten therapeutic clusters, the regulatory frame and the full arc from protocol to publication.
From clinical to real-world data. We manage both.
Totally digital. Tell us what you need to prove.